Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M33yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrwPZB6UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> MWeyOVk3ODJ6Mh?=
KellyCis83 M3jjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HoSWlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= NGHoPY0zPTl4MEK4Ni=>
SK-N-AS NEDtb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH0Z|ZKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NGrVZpAzPTl4MEK4Ni=>
SK-N-ASCis24 M3fjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLrTWM2OD1yLkW35qCKyrIkgJmwMlEyKM7:TR?= M4S2SFI2QTZyMkiy
U87 NUHBS2VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknLNE02OCEQvF2= M3v6[VQ5KGh? NEXxZlZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= MnjKNlU4PTB{N{O=
HCT116 M4nIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHONE42NTJwNTFOwG0> MV[0POKhcMLi NYnXdmZnUUN3ME2xMlc{yqEEsdMgNE4zOcLizszN MVKyOVc1Pjd4Mx?=
HT-29 NHPpNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK0NE42NTJwNTFOwG0> NGXFZXo1QMLiaNMg NWDpd2dmUUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= NF\le4IzPTd2Nke2Ny=>
Caco2 M2fyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rtRVAvPS1{LkWg{txO M3\3cVQ5yqCqwrC= NGXUNnZKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= M1LMS|I2PzR4N{[z
COLO 205 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;GNE42NTJwNTFOwG0> MlK2OFjDqGkEoB?= MnK0TWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NY\H[4lWOjV5NE[3OlM>
SW480 M2DlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorYNE42NTJwNTFOwG0> NEXwcFk1QMLiaNMg NYjZN5B4UUN3ME20MlkzyqEEsdMgNE4{O8LizszN Mn3TNlU4PDZ5NkO=
HEK293T NIHGRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0NFNsOS13IN88US=> MVy0POKhcMLi MUXJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? NYTieJZkOjV5NE[3OlM>
Hep3B  MV3GeY5kfGmxbjDBd5NigQ>? M4DmO|ExKM7:TR?= NGO4O|k1QMLiaNMg Mn3HdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> NGn5Vm8zPTZ|M{W2OC=>
Hep3B  MnHBSpVv[3Srb36gRZN{[Xl? MVKwMlEuOTBizszN M{nSNVI1KGh? NILpcnV{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= NFHRRWszPTZ|M{W2OC=>
HEK293 NHjpdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnYW|d[UUN3ME23MlE1yqEEsdMgNE4{PsLizszN M1fv[lI2PjB|MUKy
DU145 M2\ncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfQXmR[UUN3ME2yMlI5yqEEsdMgNE4xPMLizszN NGHzW48zPTZyM{GyNi=>
HCT15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXTWnpKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MV2yOVYxOzF{Mh?=
T47D NGTvTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPD[|VuUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN MX2yOVYxOzF{Mh?=
SMMC-7721 NHftRoFHfW6ldHnvckBCe3OjeR?= NHrLWWQ1OCEQvF2= NFzBPVc1QCCq M3TZ[2ROW09? M3W4VYlv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v M1Kzd|I2PTR2M{[x
MDA-MB-231 M{XPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\iNm04OsLiaB?= NHHGU29KSzVyPUKxMlLDqMLzwrC0MlLDqM7:TR?= M2jxfVI2PDh4MkG5
MCF-7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WzelczyqCq MVXJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? M1\5NVI2PDh4MkG5
Jurkat NX7yWIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Pv[VczyqCq M2PzdmlEPTB;MT6yxsDDucLiMT61xsDPxE1? MXSyOVQ5PjJzOR?=
HeLa M4LpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXcINDPzMEoHi= NVf4TYh{UUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= NITYd3ozPTR6NkKxPS=>
MCF7  NFzCWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv3OU0yODBizszN NGTDZms4KGR? M{nMeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoLINlU1PzJ4MUm=
K562 NEL0OWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn3[oo4OsLiaB?= M{XWVmlEPTB;MD6yPeKh|ryP NULDbJA2OjV{OEK2OVM>
K/VP.5 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOxW2Q4OsLiaB?= MXjJR|UxRTRwOdMg{txO NUD3XW42OjV{OEK2OVM>
SH-EP  MlWzSpVv[3Srb36gRZN{[Xl? M3vLSlIxyqEQvHevcYw> NGXSRXozPMLiaB?= M{LrVYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= NFX0N3YzPTJ4MUm4NS=>
SCC25 M{f5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSyOOKhcA>? Ml3aTWM2OD12Mz6zxsDDucLiMT6xNuKh|ryP M3nBVFI2OjJyN{K5
CAL27 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT1NlTDqGh? NVXYOnFtUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN MmTUNlUzOjB5Mkm=
FaDu MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mNlTDqGh? M{\jSWlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= MXWyOVIzODd{OR?=
SCC25 NFPSeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\lVoU1QMLiaB?= NX;HVFRHUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M2fNclI2OjJyN{K5
CAL27 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO0POKhcA>? Mnj0TWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= M3vhdVI2OjJyN{K5
FaDu NXzkOXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG0POKhcA>? NYnLXZo5UUN3ME22MlQ{yqEEsdMgNU4yO8LizszN Ml\hNlUzOjB5Mkm=
SCC25 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojpO|LDqGh? MmjFTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP M330UFI2OjJyN{K5
CAL27 NH24Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrsO|LDqGh? NHLhcIZKSzVyPUSuNlfDqMLzwrCxMlE1yqEQvF2= MorxNlUzOjB5Mkm=
FaDu MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nme|czyqCq NFXCW3pKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= M371U|I2OjJyN{K5
MCF-7 NIfVbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXiVHo1QMLiaNMg MULEUXNQ M1\Lb2lEPTB;Nz6yxsDDucLiMD64xsDPxE1? NYnjW45jOjV{MU[zO|g>
T-47D MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\kTlU1QMLiaNMg NEOwOnBFVVOR M1mxR2lEPTB;Nz63xsDDucLiMD63xsDPxE1? NYfJboREOjV{MU[zO|g>
MDA-MB-231 NYfnVWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13SSlQ5yqCqwrC= NG[5bIJFVVOR Ml[3TWM2OD1zMj64xsDDucLiMT6wxsDPxE1? NXTSbpNyOjV{MU[zO|g>
DU145 NETocIlCeG:ydH;zbZMhSXO|YYm= NYC0Xlh3OTBvMUCwJO69VQ>? MknkPEBp NF65PYZFVVOR M1jub4lv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= Mo[2NlUyPDl4OEG=
DU145 stem-like MkO0RZBweHSxc3nzJGF{e2G7 NIjhWZMyOC1zMECg{txO MXu4JIg> NVXKS3JnTE2VTx?= M3;YTIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3X3cFI2OTR7Nkix
DU145 M3jtfWZ2dmO2aX;uJGF{e2G7 NFf6OlIyOC1zMECg{txO M3vXTlIhcA>? M1rWXWROW09? M4LoSYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1XyVVI2OTR7Nkix
DU145 stem-like MVTGeY5kfGmxbjDBd5NigQ>? NYrrOmtoOTBvMUCwJO69VQ>? MXyyJIg> MXnEUXNQ M{jiXIlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlXuNlUyPDl4OEG=
UW228-3 NWDxcHBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjBdpIxNjBzLUOwNEDPxE1? NXLzbWNkPDhiaB?= M1fSPWROW09? MYnJR|UxRTBwOUpCpO69VQ>? MVqyOVEyQTF6NR?=
NSCs NFHUUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ER|AvODFvM{CwJO69VQ>? NELQ[HQ1QCCq NGftOHlFVVOR NV75eoRjUUN3ME2wMlMuO8LizszN M3j0UFI2OTF7MUi1
MKL-1  MnnRSpVv[3Srb36gRZN{[Xl? NYrr[Zd2OTBvMUCwNEBvVQ>? MUS0JIQ> NUO3SIk2cW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MX2yOVEyPjd3NB?=
MCF7 EV NV6yOWZFTnWwY4Tpc44hSXO|YYm= MkH1NVAuOTByIN88US=> MnjXNwKBkWh? NUjndHF4cW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NVHzdFA3OjVyOEiyNFM>
MCF 7BMI1 NIn4XI9HfW6ldHnvckBCe3OjeR?= M3LTdVExNTFyMDFOwG0> MWGy5qCKcA>? MUDpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> M3PDd|I2ODh6MkCz
MCF7 EV MlHtSpVv[3Srb36gRZN{[Xl? MkDTNVAuOTByIN88US=> MUWy5qCKcA>? M4\JeGVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NIL4bYczPTB6OEKwNy=>
MCF7 BMI1 MY\GeY5kfGmxbjDBd5NigQ>? NFPFNFAyOC1zMECg{txO MlWyNwKBkWh? M3vPZmVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NITiOVMzPTB6OEKwNy=>
HepG2 NELmeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LDVWROW00EoB?= NF;5OIlKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN M131b|I2ODd6M{Gx
MOLT-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLDZ441TE2VT9Mg M4HBOWlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN NV3VfJlbOjVyN{izNVE>
HT1080 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHHXXYyNTFyMDFOwG0> NIfwNnI1NzJ2L{S4JIg> MnzKSG1UV8Li MYXpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NUftbY5XOjVyN{iwOlQ>
HT1080 M{LYfWZ2dmO2aX;uJGF{e2G7 MmHWNE4xODBzLUGwNEDPxE1? NUTmOI93OS1{NDDo MkW0SG1UV8Li NE\JcW5qdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MYWyOVA4QDB4NB?=
HT1080 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPQdlJnOC5yMECxMVExOCEQvF2= M4DWO|I1KGh? M{\xTmROW00EoB?= MknsZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHSqZTDueY1j\XJib3[gZ4VtdHNiaX6gS|IwVSxid3jpcIUh\GWlcnXhd4lv\yCVIHHu[EBIOSCyaHHz[UBk\Wyucx?= NVLjfHd6OjVyN{iwOlQ>
HD-MY-Z MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3znSlI1NzR6L{eyJIg> NUHCeG5yUUN3MP-8olExOCEQvF2= M4fzb|I2ODR6MkO2
DOHH-2 M4rJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLlNlQhcA>? NFXvRVJKSzVy78{eNVAxKM7:TR?= NWfkUm81OjVyNEiyN|Y>
DOHH-2 NVPmeGoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zvb|Q5KGh? M{\FR2lEPTB;MUmuPeKh|ryP MnnaNlUxPDh{M{[=
DOHH-2 NUH6V5RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPNO|IhcA>? MojNTWM2OD13wrFOwG0> NV;iTlBrOjVyNEiyN|Y>
REH Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOyOEBp NIruTVBKSzVyPUCuNFI4yqEQvF2= M{mxUVI2ODR6MkO2
REH M1j3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPmW3I1QCCq NIjzbXFKSzVyPUCuNFE1yqEQvF2= M4TkblI2ODR6MkO2
REH MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXLO|IhcA>? M1W2cmlEPTB;MD6wNVXDqM7:TR?= NIrzPVgzPTB2OEKzOi=>
HH M2DycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1exPVI1KGh? M1Hlc2lEPTB;MUC0MlfDqM7:TR?= MXGyOVA1QDJ|Nh?=
HH NUTEW5gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XnclQ5KGh? NEntWFdKSzVyPUS4MlbDqM7:TR?= Ml24NlUxPDh{M{[=
HH NHfmeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfGO|IhcA>? Ml3tTWM2OD1zND63xsDPxE1? MUSyOVA1QDJ|Nh?=
HuT-78 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyOEBp M4nYWWlEPTB;OT6zxsDPxE1? NUP6R|dnOjVyNEiyN|Y>
HuT-78 NGTtfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYi0PEBp M3TKUWlEPTB;ND6zxsDPxE1? NUHVenlIOjVyNEiyN|Y>
HuT-78 NGjpRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjkbmM4OiCq M{X6ZmlEPTB;ND6yxsDPxE1? MlHCNlUxPDh{M{[=
OPM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBdVI1KGh? NILJT|JKSzVyPUK0MlHDqM7:TR?= NH63[3gzPTB2OEKzOi=>
OPM-2 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTBS3g1QCCq M4GzeWlEPTB;NNMg{txO Ml;KNlUxPDh{M{[=
OPM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC3NkBp NH\rUXRKSzVyPUGuN:Kh|ryP NWnkeXk1OjVyNEiyN|Y>
RPMI-8226 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfmWHFSOjRiaB?= MWXJR|UxRTFyNj62xsDPxE1? NUO2O25oOjVyNEiyN|Y>
RPMI-8226 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjs[5U1QCCq MV\JR|UxRTlzLkJCpO69VQ>? MUOyOVA1QDJ|Nh?=
RPMI-8226 NGi2W2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LCOlczKGh? NFjmbndKSzVyPUG0MlnDqM7:TR?= M4XXUFI2ODR6MkO2
U-266 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDhNlQhcA>? MlXRTWM2OD16Nj6yxsDPxE1? NV3mOIlmOjVyNEiyN|Y>
U-266 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS1cnc1QCCq MU\JR|UxRTZ6LkVCpO69VQ>? NFjxW3IzPTB2OEKzOi=>
U-266 NXq0clA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\DSHRTPzJiaB?= NHXnN5NKSzVyPUK3MlTDqM7:TR?= NYfFOllYOjVyNEiyN|Y>
Kelly MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\qcVFZOC1zMDFOwG0> M2LmXVczyqCq MYrJR|UxRTFwNUG4xsDPxE1? M3:5WVI2ODB6OUCw
SH-SY5Y  NWXWOJo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILROVcxNTFyIN88US=> M2C4NVczyqCq NIW2T3BKSzVyPUCuO|U1yqEQvF5CpC=> M{jKWVI2ODB6OUCw
SK-N-AS NEThc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\yNE0yOCEQvF2= MXm3NuKhcA>? NIXBemZKSzVyPUGuO|EzyqEQvF5CpC=> MnnmNlUxODh7MEC=
SK-N-DZ NVnsfXl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXZNE0yOCEQvF2= NYroNoxsPzMEoHi= MlriTWM2OD13LkS4OeKh|ryP NUHDfmZsOjVyMEi5NFA>
HepG2 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHzSG01QMLiaB?= NFvDZoJFVVORwrC= M{TEe2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= NVnPflhuOjR7OU[xN|Y>
A549 NGPBVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfCVW81QMLiaB?= M17mdWROW00EoB?= MXTJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NVnWdHdQOjR7OU[xN|Y>
MCF7 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T5R|Q5yqCq NV7MSZhwTE2VT9Mg MorzTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= MWSyOFk6PjF|Nh?=
HL-60  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fORVczyqCq NV[ySmdjUUN3ME2wMlEz6oDHzszN M1zzVFI1QTl|MEG0
HL-60[R] MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PuV|czyqCq NFPOc4dKSzVyPUOuNVLjiIYQvF2= NFP1SHAzPDl7M{CxOC=>
MIAPACA M1TmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTHTVUxRTFwMzFCtUAxNjB|IN88US=> MYKyOFk2Ozh{MR?=
MCF-7 M1zIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLoS2k2OD1yLkK1JOKyKDBwMTFOwG0> NGDIeIIzPDl3M{iyNS=>
HeLa M2i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjycldOT0l3ME2wMlY1KMLzIECuOEDPxE1? MVmyOFk2Ozh{MR?=
MO59K  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH0O{Bl NXfkZWxNUUN3ME2wMlE46oDHzszN MV6yOFk2OzV4MR?=
MO59J M1qxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnnd5E4KGR? M2fDXGlEPTB;MD6x5qCG|ryP MkTaNlQ6PTN3NkG=
ME 180 NYP3cVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH5OFjDqGkEoB?= MWHJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? MYqyOFk2OzB{Nx?=
MCF-7 NIrWPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr1eo81QMLiaNMg MnfkTWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? Ml\wNlQ6PTNyMke=
HeLa NYrvTWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK0POKhcMLi NWLVdoNkUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= MWKyOFk2OzB{Nx?=
MDA-MB-453 NV:1S4hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vHeVQ5yqCqwrC= M1H6dGlEPTB;MUKuOUDDuSByLki15qCG|ryP NEfKb5ozPDl3M{CyOy=>
MDA-MB-231 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFewS|k1QMLiaNMg NXTkemt5UUN3ME2yOE4zOiEEsTCyMlk16oDHzszN NX;YPHNlOjR7NUOwNlc>
PC-3 M2\TN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDMOFjDqGkEoB?= MUTJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? NWH2NnpGOjR7NUOwNlc>
HT-29 NEXVRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe0POKhcMLi NILEe21KSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= NX;1eGpIOjR7NUOwNlc>
BGC-823 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDIOFjDqGkEoB?= NEC0NYtKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= NUnUeY5VOjR5OUO4O|c>
HeLa MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLZbFhVPDkEoHlCpC=> NEDhUGNKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NXHz[GJUOjR5OUO4O|c>
A549 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm0POKhcMLi NYnoXItNUUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> Mo\VNlQ4QTN6N{e=
HK-2 NWPNdHZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXOOFjDqGkEoB?= MV\JR|UxRTlwMUegxtEhOS53OPMAie69VQ>? MX6yOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID